Nicholas Maestas
Director of Finance/CFO at TEMPEST THERAPEUTICS, INC.
Net worth: - $ as of 2024-03-30
Profile
Nicholas Maestas is currently the Secretary, Vice President-Finance & Strategy at Tempest Therapeutics, Inc. He previously worked as the Senior Director-Corporate Development & Operations at Immune Design Corp.
from 2014 to 2019 and as the Head-Financial Planning & Analysis at Alector, Inc. from 2019 to 2021.
Mr. Maestas completed his undergraduate degree at the University of California, Berkeley and holds an MBA from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-02 | 0 ( -.--% ) | - $ | 2024-03-30 |
Nicholas Maestas active positions
| Companies | Position | Start |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Director of Finance/CFO | 2021-07-11 |
Former positions of Nicholas Maestas
| Companies | Position | End |
|---|---|---|
| ALECTOR, INC. | Corporate Officer/Principal | 2021-06-30 |
| IMMUNE DESIGN CORP | Corporate Officer/Principal | 2019-06-30 |
Training of Nicholas Maestas
| University of California, Berkeley | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALECTOR, INC. | Health Technology |
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
- Stock Market
- Insiders
- Nicholas Maestas
